Amgen10-Q: Major contract lossApr 30, 2026

Otezla targeted by CMS for Medicare price setting, with declines expected in 2027.

What happened

Otezla was selected by CMS for Medicare price negotiations, which will take effect in 2027. This creates a predictable future revenue headwind, forcing the company to proactively plan for price declines and find offsetting growth.

Source

SEC EDGARApr 30, 2026

Quarterly report (Form 10-Q)

Amgen 10-Q

Filing excerpt

In January 2025, Otezla was selected by CMS for Medicare price setting that will be applicable beginning in 2027.

sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htmRead the full source

Other signals in this filing (11)

Litigation materialFacing potential $10.7B+ in back taxes and penalties from ongoing IRS disputeLitigation materialApr 30, 2026
Competitor namedProlia sales plummet 34% ($372M) due to biosimilar competition after patent expiry.Competitor namedApr 30, 2026
Competitor namedXGEVA sales fall 27% ($155M) as biosimilar competition intensifies post-patent.Competitor namedApr 30, 2026
Major contract lossENBREL sales collapse 37% ($190M) due to Medicare IRA price setting.Major contract lossApr 30, 2026
Product launchAmgen increases R&D spending by 16% ($233M) to advance late-stage pipeline, including MariTide.Product launchApr 30, 2026
Major contract winAmgen secured a $60 million order for Nplate from the U.S. government.Major contract winApr 30, 2026
Market share lossProlia sales plummet 34% YoY due to biosimilar competition and patent expiryMarket share lossApr 30, 2026
Pricing pressureENBREL sales drop 37% due to 15% price decline from IRA Medicare price settingPricing pressureApr 30, 2026
Market share lossXGEVA sales fall 27% YoY as biosimilar competition intensifies after patent expiryMarket share lossApr 30, 2026
Market expansionMultiple new products show explosive growth, including UPLIZNA (+$171M) and IMDELLTRA (+$177M).Market expansionApr 30, 2026
Compliance burdenFacing new compliance challenges from OECD global minimum tax and new US tax law OB3Compliance burdenApr 30, 2026

Extracted by Autobound

From the Signal API record

Signal: 10-Q: Major contract loss

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end: 03/31
Filed: Apr 30, 2026

More 10-Q signals at other companies

SEC 10-QMillerKnoll, Inc.Jeffrey M. Stutz appointed Interim Chief Executive Officer.SEC 10-QSep 28, 2026
SEC 10-QCID HoldCo, Inc.Disclosed material weaknesses in financial reporting due to insufficient accounting staff and controls.SEC 10-QSep 25, 2026
SEC 10-QScholastic CorporationCore school channels decline with fewer book fairs and lower club participation.SEC 10-QSep 25, 2026

The full record

From the Signal API record

Details

CIK: 318154
Accession number: 0000318154-26-000057
Filing year: 2026
Fiscal year: 0
Why it matters: Urgency to improve
Signal category: Revenue

Topics and mentions

Vendors

Extraction

Confidence: High
Relevance: 80%
Sentiment: Negative
Detected: May 5, 2026
signal_type: sec-10q
signal_subtype: majorContractLoss

Use this data

Get every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.

Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”
MCP setup guide
Send it to your own tools
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Signal API
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

linkedin_urlValue in the API
industriesValue in the API
employee_count_lowValue in the API
employee_count_highValue in the API
revenueValue in the API
descriptionValue in the API

Signal

signal_nameValue in the API
associationValue in the API

Start Free1,000 free creditsUse it in Claude via MCP

Show the full JSONThe record on this page and the API request

GET /v1/signals/d0210606-81bc-4606-ab8d-60a76fa2d3ef returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "d0210606-81bc-4606-ab8d-60a76fa2d3ef",
  "signal_type": "sec-10q",
  "signal_subtype": "majorContractLoss",
  "detected_at": "2026-05-05T08:48:22.5+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "Otezla was selected by CMS for Medicare price negotiations, which will take effect in 2027. This creates a predictable future revenue headwind, forcing the company to proactively plan for price declines and find offsetting growth.",
    "summary": "Otezla targeted by CMS for Medicare price setting, with declines expected in 2027.",
    "excerpts": "In January 2025, Otezla was selected by CMS for Medicare price setting that will be applicable beginning in 2027.",
    "relevance": 0.8,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htm",
    "filing_date": "2026-04-30",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/31",
    "sales_relevance": "Urgency to improve",
    "signal_category": "revenue",
    "vendors_mentioned": [
      "CMS"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/d0210606-81bc-4606-ab8d-60a76fa2d3ef \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.